Early-onset colorectal cancer (EOCRC), largely defined as the diagnosis of colorectal cancer in pa-tients younger than 50 years old, has shown a global increase in incidence, which is a growing cause of concern warranting increased awareness and preventive research. The incidence of EOCRC varies with factors like age, gender, and ethnicity, showing the greatest incidence among men, Hispanic patients, and Black patients. Associated risk factors include family history and environmental and lifestyle factors that can lead to long-term changes in the gut microbiome. In EOCRC, there is a preponderance of rectal and left-colonic involvement, a higher proportion of unfavorable histology, and an advanced stage of disease at presentation. Despite efforts to increase awareness, EOCRC patients face worse outcomes, with mortality rates increasing by 1.3% annually, mainly due to a lack of established screening methods. Challenges include financial burdens, fertility risks, and mental health struggles, necessitating multidisciplinary care. Early detection through targeted screening is vital to improve the prognosis of patients with EOCRC. Additionally, healthcare access and EOCRC awareness should be improved for better long-term outcomes.
The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing globally, and PDAC remains one of the deadliest malignancies, primarily because of late-stage presentation at diagnosis and limited effective therapies. KRAS mutations are present in approximately 88–92% of PDAC cases, making KRAS an important therapeutic target in PDAC, despite its long-standing historical classification as being “undruggable.” This review comprehensively examines the role of KRAS in pancreatic cancer and summarizes both indirect and direct KRAS-targeted therapeutic strategies, including downstream pathway inhibition, metabolic targeting, and emerging direct KRAS inhibitors. The ongoing clinical trials are essential for establishing the efficacy of these emerging therapies, which are poised to gradually transition into clinical practice and ultimately improve patient outcomes. A major challenge with KRAS-targeted therapy is drug resistance, which occurs through both on-target and bypass mechanisms, but emerging combination strategies targeting parallel pathways show promise. Combination approaches involving chemotherapy, immunotherapy, PRMT5 inhibition, and tumor microenvironment targeting are being actively studied to overcome resistance. Overall, KRAS-directed therapies represent a significant and evolving advancement with the potential to improve outcomes in pancreatic cancer.